GlassScriptPhysician profile
Hiren Patel
NPI 1730479486
$3,610.46
in general payments reported to CMS, 2019-2025
20 companies · $609 in 2025
The $609 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.52 · 2020: $133 · 2021: $218 · 2022: $93.46 · 2023: $1,201 · 2024: $1,301 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,928 · Travel and Lodging: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,928.35 |
| Travel and Lodging | $1,182.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,653.71 | 2023-2025 | Amvia Edge, Pamira, Selectra |
| Stryker Corporation | $521.27 | 2023 | N/A, Yukon Oct Spinal System |
| Boston Scientific Corporation | $283.02 | 2021-2025 | Ams 700, Wavewriter Alpha Prime 16, Dreamtome Rx 49 |
| Abbott Laboratories | $219.81 | 2025 | Ensite |
| Edwards Lifesciences Corporation | $145.23 | 2021 | |
| Akcea Therapeutics, INC. | $133.42 | 2020 | |
| Novartis Pharmaceuticals Corporation | $110.28 | 2023-2024 | |
| Heartflow, INC. | $99.34 | 2023 | Ffrct |
| Actelion Pharmaceuticals US, INC. | $66.03 | 2021-2025 | Uptravi, Opsumit |
| Pfizer INC. | $63.15 | 2019-2024 | |
| Insmed, INC. | $50.31 | 2022-2024 | Arikayce |
| Janssen Pharmaceuticals, INC | $48.98 | 2022 | |
| Sanofi-Aventis U.S. LLC | $46.46 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.60 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $41.55 | 2023-2024 | Brilinta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.87 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.25 | 2023 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.53 | 2024 | Lifevest |
| Scpharmaceuticals INC. | $17.16 | 2023 | |
| Merck Sharp & Dohme LLC | $14.49 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hiren Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.